Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31358862 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL15986104 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL31711351 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL13855547 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL17392871 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL1243678 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL358468 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL308741 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL2386271 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL20162089 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | NOD1 1558/4885CASP2 1386/4885GNAI3 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.